Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Paparel

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
World Journal of Urology|November 26, 2025
Local recurrence after R0 partial nephrectomy for RCC: insights from a large multicenter cohort (PREPARE study - UroCCR 140)Lucas Deluegue, Gaëlle Margue, Laurine Cadart, et al.
European Urology Oncology|June 27, 2024
Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175)Julien Sarkis, Cecile M Champy, Nicolas Doumerc, et al.
BJU International|January 17, 2023
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)Astrid Boulenger de Hauteclocque, Loïc Ferrer, Damien Ambrosetti, et al.
Clinical Genitourinary Cancer|November 12, 2013
Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomesPierre Bigot, Jean-François Hétet, Jean-Christophe Bernhard, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
European Urology|March 8, 2011
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general populationYann Neuzillet, Xavier Tillou, Romain Mathieu, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
World Journal of Urology|November 26, 2025
Local recurrence after R0 partial nephrectomy for RCC: insights from a large multicenter cohort (PREPARE study - UroCCR 140)Lucas Deluegue, Gaëlle Margue, Laurine Cadart, et al.
European Urology Oncology|June 27, 2024
Robot-assisted Partial Nephrectomy for Hilar and Nonhilar Renal Masses: Comparison of Perioperative, Oncological, and Functional Results in a Multicentre Prospective Cohort (NEPRAH Study, UroCCR 175)Julien Sarkis, Cecile M Champy, Nicolas Doumerc, et al.
BJU International|January 17, 2023
Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15)Astrid Boulenger de Hauteclocque, Loïc Ferrer, Damien Ambrosetti, et al.
Clinical Genitourinary Cancer|November 12, 2013
Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomesPierre Bigot, Jean-François Hétet, Jean-Christophe Bernhard, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
European Urology|March 8, 2011
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general populationYann Neuzillet, Xavier Tillou, Romain Mathieu, et al.
Pageof 9